Updates are available Correction dated 2023-04-25

Article History

Received: 11 November 2022

Accepted: 19 December 2022

First Online: 19 January 2023

Change Date: 25 April 2023

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1186/s42466-023-00242-y

Declarations

:

: This study was performed in line with the principles of the Declaration of Helsinki. The local ethics committee of the Medical Faculty of Heidelberg University approved the study (S-535/2022). Because of the study character, patients’ consent was waived.

: Not applicable.

: TR received consulting honoraria, speakers’ honoraria and travel support from BMS Pfizer, Boehringer Ingelheim, Bayer HealthCare and Daiichi Sankyo, outside the submitted work. DGN reports speaker´s honoraria and consulting fees from AstraZeneca, Bayer Healthcare, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, and Medtronic, outside the submitted work. KGH reports speaker´s honoraria, consulting fees, lecture honoraria and/or study grants from Abbott, Amarin, Alexion, AstraZeneca, Bayer Healthcare, Sanofi, Biotronik, Boehringer Ingelheim, Bristol-Myers Squibb, Boston Scientific, Daiichi Sankyo, Medronic, Novartis, Pfizer, Portola, SUN Pharma, W.L. Gore and Associates and Edwards Lifesciences, outside the submitted work. PR received lecture honoraria from Boehringer Ingelheim, Bayer, PFIZER and Daiichi Sankyo and for advisory board activities from Boehringer Ingelheim and Pfizer, outside the submitted work. TR and PR are members of the editorial board of Neurological Research and Practice.